Antihypertensive medication adherence trends by sex and drug class: A pilot study.
Antihypertensive drugs
blood pressure
nonadherence
sex differences
treatment resistant hypertension
Journal
American heart journal plus : cardiology research and practice
ISSN: 2666-6022
Titre abrégé: Am Heart J Plus
Pays: United States
ID NLM: 101779333
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
19
04
2021
revised:
11
05
2021
accepted:
10
06
2021
medline:
24
6
2021
pubmed:
24
6
2021
entrez:
1
4
2024
Statut:
epublish
Résumé
Antihypertensive medication nonadherence is a prevalent issue but is very difficult to accurately assess. To clarify this problem among hypertensive patients attending a cardiovascular disease outpatient clinic, we utilized high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS) to assess antihypertensive medication adherence and identify trends by sex and drug class. Serum was extracted from blood samples obtained from patients with either drug-controlled or drug resistant hypertension (RHTN) and analyzed via HPLC-MS for antihypertensive drugs which were categorized by drug class as beta blockers, aldosterone antagonists, diuretics, ACE inhibitor/ARBs, or calcium channel blockers. Clinic blood pressure (BP), sex, and prescription regimens were extracted from medical records at or near the time of blood collection. "Adherence" or "nonadherence" was determined by comparison of the patient's prescribed drug regimen and the presence/absence of prescribed drug(s) in their serum. Among 76 patients (47 women; mean age 63; 53% white), nonadherence was confirmed in 29%. RHTN was more frequently identified in women than men (55% vs 38%) and nonadherence was higher in women than men (34% vs 21%). BP in those who were adherent to prescribed antihypertensive drugs was significantly lower than in those who were nonadherent (129/75 vs 145/83 mmHg, We observed nonadherence was more frequent among older women in a cohort of HTN and RHTN patients with cardiovascular disease based on HPLC-MS confirmed drug levels.
Identifiants
pubmed: 38560412
doi: 10.1016/j.ahjo.2021.100023
pii: S2666-6022(21)00021-5
pmc: PMC10976189
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100023Informations de copyright
© 2021 The Authors.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that couple have appeared to influence the work reported in this paper.